Travere Therapeutics
TVTX
148 hedge funds and large institutions have $1.48B invested in Travere Therapeutics in 2021 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 43 increasing their positions, 53 reducing their positions, and 21 closing their positions.
300% more funds holding in top 10
Funds holding in top 10: 1 → 4 (+3)
64% more capital invested
Capital invested by funds: $900M → $1.48B (+$577M)
62% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 21
22% more call options, than puts
Call options by funds: $6.19M | Put options by funds: $5.08M
9% more funds holding
Funds holding: 136 → 148 (+12)
1.07% less ownership
Funds ownership: 101.35% → 100.28% (-1.1%)
19% less repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 53
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$34M |
| 2 |
VA
VR Adviser
New York
|
+$31.8M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$14.3M |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$8.03M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$6.63M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$34.8M |
| 2 |
Goldman Sachs
New York
|
-$25.1M |
| 3 |
AC
Armistice Capital
New York
|
-$18.4M |
| 4 |
D.E. Shaw & Co
New York
|
-$14.6M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$13.2M |
TVTX Hedge Fund Activity: Q3 2021 in Review
148 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q3 2021, worth a combined $1.48B — up 64% from $900M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new TVTX positions and 21 closed out — a net gain of 13 holders — while 43 added to existing stakes and 53 trimmed.
The largest buyer was Baker Bros. Advisors, adding an estimated $34M. The largest seller was Adage Capital Partners, cutting an estimated $34.8M.
- 148 institutional investors held Travere Therapeutics (TVTX) as of Q3 2021, up from 136 in Q2 2021.
- Funds reported $1.48B of Travere Therapeutics stock for Q3 2021, up 64% quarter-over-quarter.
- 34 funds opened new Travere Therapeutics positions in Q3 2021 and 21 closed out, a net change of +13 holders.
- The largest Travere Therapeutics buyer in Q3 2021 was Baker Bros. Advisors, an estimated $34M added.
- The largest Travere Therapeutics seller in Q3 2021 was Adage Capital Partners, an estimated $34.8M sold.
Based on aggregated 13F filings for Q3 2021.